A Phase 2 Randomized Double-blind Study of Glutaminase Inhibitor Telaglenastat with Pembrolizumab and Chemotherapy vs Placebo with Pembrolizumab and Chemotherapy in Front-line Metastatic KEAP1/NRF2- mutated Nonsquamous Non-Small Cell Lung (NSCLC)

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Non-small Cell Lung Cancer (nsclc)
  • Age: Between 18 - 100 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1) histologically or cytologically documented stage IV (M1a-c) nonsquamous NSCLC with a KEAP1 or NRF2 mutation and no other known actionable mutation and no previous treatment with systemic therapy for the metastatic NSCLC.

You may not be eligible for this study if the following are true:

  • 1) Patients with squamous cell NSCLC or any component of small cell histology are not eligible.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.